GlobeNewswire

Juniper Networks Wins "Best of Show" Top Awards at Interop Tokyo 2018

Dela

Juniper's MX10008 Universal Chassis and Contrail Enterprise Multicloud Emerge as Grand Prix Winners at Prestigious Awards Ceremony

 

TOKYO, June 14, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE:JNPR), an industry leader in automated, scalable and secure networks, today announced that it has captured multiple top honors at Interop Tokyo 2018 for the 12th straight year. The recognition reflects the company's consistent commitment toward delivering innovative and industry-leading networking technology while simplifying the complexities of networking.

Maintaining its award winning-streak at the influential trade show, Juniper triumphed in the following categories this year:

  • "Best of Show" Grand Prix Award (Network Infrastructure): Juniper Networks MX10008 Universal Chassis
  • "Best of Show" Grand Prix Award (Cloud Computing): Contrail Enterprise Multicloud by Juniper Networks
  • "Best of Show" Runners-Up Award (Security): Juniper Networks ATP Appliance
  • "Best of Show" Special Award (Security): Juniper Networks SRX4600 Services Gateway

Continuing Juniper's proud tradition of receiving consecutive "Best of Show" awards at Interop Tokyo since 2007, a prominent judging panel of industry experts and executives selected Juniper's products as award winners from among hundreds of nominations across the industry. Recent Juniper award-winners have included the QFX10008QFX5110 and the MX10003.

As one of the largest network computing trade shows in Asia, Interop Tokyo is renowned for being a top global business technology event, showcasing the very latest in cutting-edge networking products, solutions and services from vendors across the world. This year, Interop Tokyo 2018 attracted more than 140,000 attendees (including co-located events) and featured major keynote addresses and full-fledged conference programs, as well as an associated expo area for showcases by vendors.

Product Highlights:

Juniper Networks MX10008 Universal Chassis

  • The MX10008 completes Juniper's universal chassis portfolio that also includes the PTX and QFX chassis and continues service-scale innovation to usher in the next era of carrier, enterprise and cloud networking.
  • Customers now can have a singular chassis to accommodate a variety of line cards and software for different use-cases, enabling customers to do more with less while simplifying network design and reducing OPEX.
  • In addition, the MX10008 also brings industry-leading and space-saving scale for edge routers at 19.2 Tbps, while also improving per-slot economics for service scale at ~0.6 watts per gigabit.

Contrail Enterprise Multicloud by Juniper Networks

  • Contrail Enterprise Multicloud is the only multicloud-ready orchestration and analytics platform, for any cloud and any workload, across multivendor environments.
  • Integrating both overlay and underlay management into an open platform, Contrail Enterprise Multicloud streamlines workflows and improves end-to-end visibility.
  • Featuring end-to-end policy and control capability, Contrail Enterprise Multicloud enables users to have a single tool for orchestration across overlay and fabric management, bare metal servers, virtual machines, containers and networking devices, private and public clouds and security management.
  • Based on open interfaces and standard protocols, Contrail Enterprise Multicloud can be inserted into diverse networking environments to avoid unnecessary vendor lock-in, all while enabling a clear path toward a secure and automated multicloud.

Juniper Networks Advanced Threat Prevention (ATP) Appliance

  • The ATP Appliance provides comprehensive on-premise protection against a sophisticated ever-changing threat landscape.
  • Utilizing advanced machine learning and behavioral analysis, the ATP Appliance identifies existing and unknown advanced threats in near real-time.
  • With an open API architecture, the ATP Appliance integrates with third-party security devices for seamless, automatic threat mitigation.
  • The ATP Appliance is available in both physical (all-in-one or distributed mode deployment) and virtual (distributed mode only) form factors.

Juniper Networks SRX4600 Services Gateway

  • The high-performance SRX4600 next-generation firewall offers fast, scalable protection across the enterprise private cloud, campus networks, cloud service providers and telcos alike
  • With integrated malware prevention and a full suite of next-generation services, the SRX4600 is optimized to provide consistent and seamless protection across diverse environments
  • As the center point of defense, the SRX4600 offers unprecedented command over your entire security infrastructure, allowing for 'single pane of glass' management through Junos Space Security Director

Supporting Quote

"We are delighted to once again continue Juniper Networks' proud tradition of capturing multiple prestigious awards at Interop Tokyo, across the Network Infrastructure, Cloud Computing and Security categories. It's a major honor to be consecutively recognized every year since 2007 by the esteemed panel, and a strong testament to our commitment of continually challenging the complexities across networking - all while consistently engineering industry-leading products and solutions for our customers."

- Mike Marcellin, SVP and chief marketing officer, Juniper Networks

Additional Resources:

About Juniper Networks
Juniper Networks simplifies the complexities of networking with products, solutions and services in the cloud era to transform the way we connect, work and live. We remove the traditional constraints of networking to enable our customers and partners to deliver automated, scalable and secure networks that connect the world. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on TwitterLinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper and Junos are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Media Relations:
Juniper Networks
Kenneth Chew
+65 6511 3529
kchew@juniper.net




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Juniper Networks via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum